AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02133339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03966170
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo drug
Trial: NCT04591626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01107236
Drug: IW-6118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT01107236
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
Trial: NCT01107236
Drug: Naproxen Sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT00913107
Drug: Lamictal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days.
Trial: NCT00913107
Drug: Tegretol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days.
Trial: NCT01924000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01270048
Drug: mild-ex-gwarip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
Trial: NCT02994056
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily
Trial: NCT03421860
Drug: cardiac output changes with nor-epinephrine
RxNorm normalized name: Sensorcaine with Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
Trial: NCT01314742
Drug: Biotene OralBalance® gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
Trial: NCT04872322
Drug: Percocet Pill
RxNorm normalized name: Percocet Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgery participants will be given a prescription for Percocet to be taken as needed for pain
Trial: NCT04872322
Drug: Norco Pill
RxNorm normalized name: Norco Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgery participants will be given a prescription for Norco to be taken as needed for pain
Trial: NCT02061774
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram of intravenous Acetaminophen
Trial: NCT02061774
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
Trial: NCT03526965
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention included pain medications and exercise movements for neck.
Trial: NCT00372788
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral vial
Trial: NCT03301909
Drug: Bowel prep combination
RxNorm normalized name: bowel prep combination no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject may be assigned to any bowel preparation combination.
Trial: NCT04578470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two tablets daily for 13weeks then 1 tablet daily for13 weeks
Trial: NCT00855283
Drug: IN NEO
RxNorm normalized name: Neosporin Neo To Go!
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Neostigmine via intranasal and sublingual administration
Trial: NCT00855283
Drug: IN NEO
RxNorm normalized name: Neosporin Neo To Go!
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Neostigmine via intranasal administration
Trial: NCT00855283
Drug: IN NEO
RxNorm normalized name: Neosporin Neo To Go!
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Neostigmine via intranasal administration
Trial: NCT00547573
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet taken by mouth as needed for 12 weeks not more than once a day
Trial: NCT00223015
Drug: Fluvastatin, Tacrolimus, Mycophenolat Mofetil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00904397
Drug: Lidoderm®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
Trial: NCT00855283
Drug: IN NEO + IN Glycopyrrolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
Trial: NCT00855283
Drug: IV Visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
Trial: NCT01925313
Drug: CJ-30044
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20.51mg a day,PO,QD
Trial: NCT01925313
Drug: TALION TAB. 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg a day,PO,BID
Trial: NCT00904397
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
Trial: NCT00978978
Drug: Propofol VS. midazolam and fentanyl, endoscopies, liver diseases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~2. Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists
Trial: NCT03559387
Drug: ANF-RHO™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the ANF-RHO™ treatment arm will receive the investigational product on Day 1(day of chemotherapy treatment) of each Chemotherapy cycle. ANF-RHO™ will be administered to the subjects as a subcutaneous injection. Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg.~ANF-RHO™ is provided as a single-use glass vial containing 1.0 ml of solution at a concentration of 5 mg/ml
Trial: NCT03559387
Drug: Neulasta®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the Neulasta® treatment arm will receive the comparator drug on Day 2(day after chemotherapy treatment) of each Chemotherapy cycle. Neulasta® will be administered to the subjects at a standard dose of 6.0 mg in 0.6 ml as a subcutaneous injection.~Neulasta® is also provided as a single-use pre-filled syringe.
Trial: NCT03673059
Drug: OTC Eczema Moisturizer Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
Trial: NCT04061265
Drug: lidocaine hydrochloride 2% and epinephrine 1:100000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic agent
Trial: NCT02739542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
Trial: NCT00922532
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
Trial: NCT00922532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen gas will be administered in the same manor as the experimental drug
Trial: NCT03094429
Drug: NaBen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg/day or 1000 mg/day, twice daily
Trial: NCT03363269
Drug: ID1201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01984788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01395953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
Trial: NCT00743197
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg every night
Trial: NCT01104662
Drug: Semi-Synthetic Penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02627027
Drug: Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02627027
Drug: CKD-395 0.25/750mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01479478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule daily.
Trial: NCT00313885
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT04620109
Drug: KDR2-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization.
Trial: NCT04620109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .
Trial: NCT02070744
Drug: Placebo matched to VX-661
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral use
Trial: NCT00567307
Drug: Red Heart Pill 2b (Polypill)
RxNorm normalized name: Tri-Heart Plus Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
Trial: NCT01575678
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: blinded capsule 2-4 mg/day, oral use, for 4 weeks
Trial: NCT01575678
Drug: Lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blinded capsule 1/day, oral use, for 4 weeks
Trial: NCT01096290
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily for 30days, oral
Trial: NCT01737320
Drug: short-course antibiotic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~1. Intervention group - antibiotic treatment stopped on day 7~2. Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines.
Trial: NCT01737320
Drug: accepted prolonged antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01611090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=capsule, route=oral use. Capsule is taken once daily continuously.
Trial: NCT02249884
Drug: Urea Dose A
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea cream for topical use.
Trial: NCT02249884
Drug: Urea Dose B
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea cream for topical use.
Trial: NCT02249884
Drug: Urea Dose C
RxNorm normalized name: Urea C 13
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Urea cream for topical use.
Trial: NCT02158936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag matching placebo tablets
Trial: NCT02158936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag matching placebo tablets will be supplied
Trial: NCT02602184
Drug: AR/101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02602184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00944970
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
Trial: NCT01151813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01026961
Drug: Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
Trial: NCT02178709
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle.
Trial: NCT01572649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Trial: NCT04254107
Drug: SEA-TGT
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
Trial: NCT00889590
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
Trial: NCT01335477
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching BIBF 1120 BID
Trial: NCT01335477
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 BID (twice daily)
Trial: NCT03577626
Drug: Hemay005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
Trial: NCT03577626
Drug: Hemay005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
Trial: NCT04642950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of physiological saline will be administered using inhaler twice daily in approximately 10-15 minutes.
Trial: NCT03717064
Drug: RO7049389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
Trial: NCT01298570
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
Trial: NCT01298570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
Trial: NCT03508713
Drug: disease modified antirheumatic drugs or biological agents
RxNorm normalized name: LIPID MODIFYING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
Trial: NCT03237819
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)
Trial: NCT00917501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given twice a day which will be compared to Omega 3
Trial: NCT00747331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug
Trial: NCT02548533
Drug: AHES
RxNorm normalized name: STOMAHESIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
Trial: NCT01479881
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
Trial: NCT02623959
Drug: Fentanyl (IV)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 50 mcg given by vein prior to catheter draining.
Trial: NCT02623959
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
Trial: NCT03057899
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
Trial: NCT03562533
Drug: pegylated liposomal doxorubicin (PLD) + carboplatin (CD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
Trial: NCT02445508
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01286233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04095299
Drug: Capecitabine 825 mg/m2 twice daily on weekdays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy
Trial: NCT03093454
Drug: Lavender Essential Oil
RxNorm normalized name: Nature's Truth Lavender Essential Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender essential oil will be applied topically and by inhalation to the lavender group.
Trial: NCT04033575
Drug: Colgate Total SF
RxNorm normalized name: Colgate Total SF Whitening Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
Trial: NCT00421174
Drug: Placebo plus corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
Trial: NCT00067405
Drug: Intravenous micronutrient therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00550121
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003696
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003696
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04249531
Drug: Amikacin Inhalation Dry Powder
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg